Peer-reviewedCC BYJournal of clinical medicine23 Sep 2026

Comparative Safety Profiles of Sacituzumab Govitecan and Datopotamab Deruxtecan: A Real-World Pharmacovigilance Study

Ziya Kalkan¹
Murat Bardakci²
Tugba Tezer Kalkan²
Yakup Ergun³

¹Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır 21280, Türkiye
²Department of Medical Oncology, Gazi Yaşargil Training and Research Hospital, Diyarbakır 21010, Türkiye
³Department of Medical Oncology, Bower Hospital, Diyarbakır 21100, Türkiye

514 Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBC
Ke Liu, Kevin Chin, Zhen Su +14
Journal for ImmunoTherapy of Cancer6 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
Efficacy and safety of sacituzumab govitecan in metastatic breast cancer: a single-center retrospective cohort study
Orcun Can, Osman Gökhan Demir
Frontiers in Oncology13 Oct 2026Peer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis.
Binliang Liu, Tao Wu, Fang Xu +7
Health economics review1 Jul 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCDOAJ
Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial
Shaohua Zhang, Jianli Zhao, Xiaoling Ling +4
Translational Breast Cancer Research15 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer
Zuojuan Xiang, Qiao Xia, Zhengxiong Li
Frontiers in Pharmacology6 Nov 2026Peer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref

Cite

BibTeX

@article{kalkan2026comparative,
  title = {{Comparative Safety Profiles of Sacituzumab Govitecan and Datopotamab Deruxtecan: A Real-World Pharmacovigilance Study}},
  author = {Ziya Kalkan and Murat Bardakci and Tugba Tezer Kalkan and Yakup Ergun},
  journal = {Journal of clinical medicine},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13665492},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Comparative Safety Profiles of Sacituzumab Govitecan and Datopotamab Deruxtecan: A Real-World Pharmacovigilance Study
AU  - Ziya Kalkan
AU  - Murat Bardakci
AU  - Tugba Tezer Kalkan
AU  - Yakup Ergun
PY  - 2026
DA  - 2026/09/23
JO  - Journal of clinical medicine
UR  - https://europepmc.org/article/PMC/PMC13665492
SN  - 2077-0383
ER  -

Related

Cite